Abbott announced the scheduled close of its $23 billion acquisition of Exact Sciences after receiving final regulatory clearances. The deal brings Cologuard, Oncotype DX, Oncodetect and Cancerguard into Abbott’s diagnostics portfolio, and the company expects roughly $3 billion of incremental sales by 2026. Exact shareholders previously approved the transaction and Abbott accessed debt markets to fund the purchase. Abbott framed the transaction as a strategic expansion into cancer screening and molecular diagnostics that strengthens its diagnostics leadership and long‑term growth profile. Management disclosed an anticipated short‑term EPS dilution of about $0.20 and modest near‑term share impacts, but emphasized the revenue upside from adding multi‑cancer and MRD capabilities to its diagnostics lineup.